Wang Chih-Chun, Yeh Shyh-An, Chen Wen-Hui, Li Hung-Ju, Yang Chuan-Chien, Huang Tse-Jen, Su Yu-Chieh
Department of Otolaryngology, E-Da Hospital, I-Shou University, Kaohsiung 82445, Taiwan.
School of Chinese Medicine for Post-Baccalaureate, College of Medicine, I-Shou University, Kaohsiung 82445, Taiwan.
Cancers (Basel). 2025 Jan 10;17(2):210. doi: 10.3390/cancers17020210.
BACKGROUND/OBJECTIVES: The aim of this study is to assess the effectiveness of cetuximab combination therapy in patients with recurrent or metastatic head and neck cancer treated at a hospital in Southern Taiwan.
This study analyzed a retrospective cohort of 67 patients who were treated between January 2020 and May 2024 with two cetuximab regimens, cetuximab combined with cisplatin and 5-Fu, which were administered every four weeks during hospitalization (CPF4) and every two weeks as outpatient treatment (CPF2), respectively. The clinical outcomes, including overall survival and progression-free survival (PFS), were compared across the treatment regimens and age groups using Kaplan-Meier survival curves and Cox proportional hazard models.
The median overall survival was 11.1 months (95% confidence interval, 7.8-14.5), with CPF2 showing a potential PFS advantage in patients aged 46-60 years ( = 0.049). No significant differences in overall survival were observed between CPF2 and CPF4. CPF2, which was administered in an outpatient setting, was associated with improved convenience, reduced hospitalization, and potentially lower risks of hospital-acquired infections.
CPF2 exhibits practical advantages and comparable effectiveness, making it the preferred treatment regimen for eligible patients. Further studies with larger populations and molecular stratifications are needed to confirm these findings and develop better treatment strategies.
背景/目的：本研究旨在评估西妥昔单抗联合疗法对在台湾南部一家医院接受治疗的复发性或转移性头颈癌患者的疗效。
本研究分析了一个回顾性队列，该队列由67例患者组成，他们在2020年1月至2024年5月期间接受了两种西妥昔单抗治疗方案，即西妥昔单抗联合顺铂和5-氟尿嘧啶，分别在住院期间每四周给药一次（CPF4）和作为门诊治疗每两周给药一次（CPF2）。使用Kaplan-Meier生存曲线和Cox比例风险模型比较了各治疗方案和年龄组的临床结局，包括总生存期和无进展生存期（PFS）。
中位总生存期为11.1个月（95%置信区间，7.8 - 14.5），CPF2在46 - 60岁患者中显示出潜在的PFS优势（P = 0.049）。CPF2和CPF4之间在总生存期方面未观察到显著差异。在门诊环境中给药的CPF2具有更高的便利性、减少了住院时间且潜在的医院获得性感染风险更低。
CPF2具有实际优势且疗效相当，使其成为符合条件患者的首选治疗方案。需要进一步开展更大规模人群和分子分层的研究以证实这些发现并制定更好的治疗策略。
